Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Independent ethics committee curbs seen hurting Indian studies

This article was originally published in Scrip

Executive Summary

Following on from the Supreme Court of India issuing strict time-bound instructions to the government concerning the regulatory regime for clinical trials, a recent notice restricting the scope of activities of independent ethics committees (ECs) is expected to have a crushing impact on investigator-led and postmarketing studies in the country.

You may also be interested in...



Sun Loses Shine Amid Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite

High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.

Top-Level Churn At Cipla's India Business

A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel